CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.
Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074
E-mail : concorddrugsltd@gmail.com Ph.No : +91 9052779505 Website : www.concorddrugs.in

Date: 07.09.2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal St, Fort, Mumbai,
Maharashtra 400001

Scrip Code: 538965

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of Concord Drugs Limited ("the Company") at its meeting held today, i.e., Monday, 07th September, 2026, inter-alia, transacted and approved the following businesses:

1. Approval of Notice and Annual Report

Approved the Notice of the 31st Annual General Meeting of the Company to be held on Wednesday, 30 September 2026 at 09:30 A.M. (IST) through Video Conferencing / Other Audio Visual Means (VC/OAVM).

The Board also approved the Directors' Report and Annual Report of the Company for the financial year 2025–26, together with the Corporate Governance Report and other statutory reports forming part thereof and approved the issue of the Notice of the AGM and Annual Report to the Members

2. Book Closure and Cut-off Date

The Board approved the closure of the Register of Members and Share Transfer Books of the Company from 24 September 2026 to 30 September 2026, both days inclusive, for the purpose of the 31st Annual General Meeting.

The Board also approved 23 September 2026 as the Cut-off Date/Record Date for determining the eligibility of members to vote through remote e-voting at the ensuing Annual General Meeting.

3. Adoption of Financial Statements

Approved the proposal for placing before the Members for their consideration and adoption the Audited Standalone and Consolidated Financial Statements of the

Company for the financial year ended 31 March 2026, together with the Reports of the Board of Directors and Auditors thereon.

4. Re-appointment of Director Retiring by Rotation

Approved the re-appointment of Mr. S. Nagi Reddy (DIN: 01764665), Chairman & Managing Director of the Company, who retires by rotation at the ensuing Annual General Meeting and, being eligible, offers himself for re-appointment.

The requisite disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as Annexure.

5. Re-appointment of Statutory Auditors

Based on the recommendation of the Audit Committee, the Board approved the proposal for re-appointment of M/s. Pundarikashyam and Associates, Chartered Accountants (Firm Registration No. 011330S), as the Statutory Auditors of the Company for a further term of five consecutive years, from the conclusion of the 31st Annual General Meeting until the conclusion of the 36th Annual General Meeting, subject to the approval of the Members.

The proposed remuneration of the Statutory Auditors is ₹4,00,000/- (Rupees Four Lakhs only) per annum, plus applicable taxes and reimbursement of reasonable out-of-pocket expenses, as may be approved/finalised in accordance with the applicable provisions of the Companies Act, 2013.

6. Approval of Material Related Party Transactions for FY 2026–27

Approved the proposal for seeking Members' approval for material related party transactions proposed to be entered into during the financial year 2026–27 with the following related parties, within the proposed limits:

The proposed transactions are to be undertaken in the ordinary course of business and on an arm's length basis, subject to applicable laws and regulatory requirements.

7. Ratification of Remuneration of Cost Auditor

Approved the proposal for obtaining Members' approval for ratification of the remuneration payable to M/s. KJU & Associates, Cost Accountants (Registration No. 000474), appointed as Cost Auditors of the Company for the financial year 2026–27.

8. Re-appointment of Independent Director

Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the proposal for re-appointment of Mr. S. Nagavenkata Hareesh Kumar Solleti (DIN: 09066790) as an Independent Director of the Company for a second term of five consecutive years, subject to approval of the Members at the ensuing Annual General Meeting.

The requisite disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as Annexure.

9. Re-appointment of Independent Director

Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the proposal for re-appointment of Ms. Sumeela Kasu (DIN: 09571540) as an Independent Director of the Company for a second term of five consecutive years commencing from 01 June 2027 to 31 May 2032, subject to approval of the Members at the ensuing Annual General Meeting.

The requisite disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as Annexure.

The proposed re-appointment period is consistent with the current AGM Notice.

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 06:00 P.M on 07.09.2026

This is for your information and record.

Thanking you,

Yours faithfully,

For Concord Drugs Limited

Seelam Nagi Reddy

Digitally signed by Seelam Nagi Reddy
Date: 2026.09.07 18:33:52 +05'30'

S. Nagi Reddy
Chairman & Managing Director
DIN: 01764665

Annexures

Particulars	Disclosure
Reason for change	Re-appointment of Mr. Nagi Reddy as Director liable to retire by rotation, subject to approval of the Members at the 31st Annual General Meeting.
Date of appointment/re-appointment	Upon approval by the Members at the 31st Annual General Meeting.
Term of appointment/re-appointment	Re-appointment as Director liable to retire by rotation, in accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company.
Brief Profile	Mr. Nagi Reddy is a Post Graduate and has approximately 28 years of experience in the pharmaceutical industry. He has extensive experience in pharmaceutical business operations, overall management, administration and strategic planning. He has been associated with the Company for a long period and has been instrumental in guiding the Company's business and strategic affairs.
Disclosure of relationships between Directors	Mr. Nagi Reddy is the father of Mr. Koni Reddy and Mr. Manoj Reddy, who are Directors of the Company.
Shareholding in the Company	30,60,536 Equity Shares.
Information under Regulation 30	There is no other material information required to be disclosed in relation to the aforesaid re-appointment.
Debarment	Mr. S. Nagi Reddy is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority

Particulars	Disclosure
Reason for change	Re-appointment of Mr. S. Nagavenkata Hareesh Kumar Solleti as an Independent Director of the Company for a second term, subject to approval of the Members by way of Special Resolution.
Date of appointment/re-appointment	To be effective from the date of approval by the Members, subject to applicable provisions of the Companies Act, 2013 and SEBI LODR Regulations.
Term of appointment/re-appointment	Proposed re-appointment for a second term of five consecutive years, subject to approval of the Members.
Brief Profile	Mr. S. Nagavenkata Hareesh Kumar Solleti (DIN: 09066790) is a qualified professional with experience in the areas of management and administration. He has been associated with the Company as an Independent Director and has contributed to the deliberations of the Board and its Committees.
Date of Birth	23 July 1991
Qualification	Post Graduate
Date of first appointment	13 February 2021
Disclosure of relationships between Directors	He is not related to any Director or Key Managerial Personnel of the Company.
Shareholding in the Company	Nil, as per the records available to the Company.
Information under Regulation 30	There is no other material information required to be disclosed in relation to the proposed re-appointment.
Debarment	Mr. S. Nagavenkata Hareesh Kumar Solleti is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Particulars	Disclosure
Reason for change	Re-appointment of Ms. Sumeela as an Independent Director of the Company for a second term, subject to approval of the Members by way of Special Resolution.
Date of appointment/re-appointment	To be effective from 01 June 2027, subject to approval of the Members and applicable provisions of the Companies Act, 2013 and SEBI LODR Regulations.
Term of appointment/re-appointment	Second term of five consecutive years from 01 June 2027 to 31 May 2032.
Brief Profile	Ms. Sumeela has been associated with the Company as an Independent Director since 01 June 2022 and has participated in the deliberations of the Board and its Committees.
Date of Birth	02 June 1976
Date of first appointment	01 June 2022
Disclosure of relationships between Directors	She is not related to any Director or Key Managerial Personnel of the Company.
Shareholding in the Company	Nil, as per the records available to the Company.
Information under Regulation 30	There is no other material information required to be disclosed in relation to the proposed re-appointment.
Debarment	Ms. Sumeela Kasu is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Particulars	Disclosure
Reason for change	Re-appointment of M/s Pundarikashyam and Associates, Chartered Accountants, as Statutory Auditors of the Company for a second consecutive term, subject to approval of the Members.
Date of appointment/re-appointment	Upon approval by the Members at the 31st Annual General Meeting.
Term of appointment/re-appointment	For a further period of five consecutive years from the conclusion of the 31st Annual General Meeting until the conclusion of the 36th Annual General Meeting of the Company.
Brief Profile	M/s Pundarikashyam and Associates is a firm of Chartered Accountants having experience in statutory audit and related professional services. The firm has been associated with the Company and is familiar with its business, operations and financial reporting requirements.
Firm Registration Number	011330S
Basis of recommendation	The Audit Committee and the Board of Directors, after considering the eligibility, professional competence, experience, independence and past performance of the firm, have recommended its re-appointment as Statutory Auditors of the Company.
Proposed remuneration	₹4,00,000 per annum plus applicable taxes and reimbursement of out-of-pocket expenses, as may be mutually agreed.
Information under Regulation 30	There is no resignation, removal or change in auditor. The proposal relates to re-appointment for a further term, subject to approval of the Members.
Eligibility and Independence	The firm is eligible for re-appointment under the applicable provisions of the Companies Act, 2013 and has confirmed its eligibility, independence and absence of disqualification for such re-appointment.